EZH2 and neoplasm: Inhibitors of EZH2 can activate the expression of deubiquitinase USP22 in colorectal cancer via canonical epigenetic regulation through H3K27me3, thereby stabilizing PD‐L1 protein and enhancing its expression, inducing immune evasion and diminishing the anti‐tumor therapeutic efficacy.